Gene edits could solve obstacles to treatment for the most common types of cancer Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to treat patients with blood cancers such as leukemia. But when it comes to treating solid tumor cancers, such as lung, breast and kidney cancers
Results of a phase 1 clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they receive the targeted therapy VIC-1911 along with the standard-of-care regimen that includes post-transplant cyclophosphamide and sirolimus. Led by Shernan Holtan, MD, Chief of Blood
Chinese researchers have developed a novel method to efficiently engineer natural killer (NK) cells for cancer immunotherapy. NK cells are central to early antiviral and anticancer defense—among other immune system roles—making them well-suited for cancer immunotherapy. For example, chimeric antigen receptor (CAR)-NK therapy involves adding a lab-built receptor (a CAR) to an NK cell, enabling
Adding a personalised mRNA vaccine to plain remedy might supply new hope for pancreatic cancer sufferers, a small but promising study from Memorial Sloan Kettering Cancer Center. The study adopted 16 sufferers, together with Barbara Brigham, who joined the trial after a routine scan found her early-stage pancreatic cancer. Alongside surgical procedure and chemotherapy, sufferers
Called PAC-MANN, the test developed at OHSU could help save lives A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers. Researchers at Oregon Health & Science University have developed a test called PAC-MANN, the abbreviation for “protease activity-based assay using a magnetic nanosensor,”
In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large Stanford Medicine study finds the risk is low and not related to the CAR-T cells. A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy — a
Combining immune-targeted therapy with chemotherapy improves both progression-free survival and overall survival when compared to those who received regorafenib alone A study(Link is external) (Link opens in new window) led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival
Approval is based on findings from the QUILT 3.032 clinical trial, which was led by UCLA’s Dr. Karim Chamie The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of
Novartis presented data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen
Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body’s immune defenses against a cancer, have not been effective for GBM, in part because the tumor’s surrounding environment is largely impenetrable to assaults from the body’s immune system.
